Vasculitis & polymyalgia rheumatica
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
Authors' conclusion
These data suggest that benralizumab could be an effective treatment for EGPA in real-life clinical practice.
Study context
- Population
- Patients with relapsing-refractory eosinophilic granulomatosis with polyangiitis (EGPA) treated with benralizumab, 28 European referral centres of the European EGPA Study Group in six countries, Jan 2019–Sep 202264 women · 57 men
- Participants
- 121 patients
- Outcome
- Complete response: BVAS of 0 and prednisone dose up to 4 mg/day
Methodological detailsmulticentre, 28 European referral centres
- Multicentre
- 28 European referral centres
Main finding
As reported in the abstract
Complete response (BVAS 0 and prednisone ≤4 mg/day) · month 12
- Complete response at month 12, 32 (46.4%, 95% CI 34.3-58.8) of 69 patients
Observational data: associations, not effects.
Further findings
Complete response at month 3
- Complete response, 15 (12.4%, 95% CI 7.1-19.6) of 121 patients
Complete response at month 6
- Complete response, 25 (28.7%, 19.5-39.4) of 87 patients
Partial response (BVAS 0 and prednisone >4 mg/day)
- Month 3: 43 (35.5%, 27.0-44.8) patients
- Month 6: 23 (26.4%, 17.6-37.0)
- Month 12: 13 (18.8%, 10.4-30.1)
BVAS, median (IQR)
- Baseline
- 3.0 (IQR 2.0-8.0)
- Months 3 and 6
- 0.0 (0.0-2.0)
- Month 12
- 0.0 (0.0-1.0)
Oral prednisone (or equivalent) dose
mg/day
- Baseline
- 10.0 (5.0-12.5)
- Month 3 (p<0.01)
- 5.0 (3.6-8.5)
- Month 6
- 5.0 (2.5-6.3)
- Month 12 (p<0.0001)
- 2.5 (0.0-5.0)
Relapse after complete response
- Patients relapsed after having a complete response
- 6
Systemic manifestations, active peripheral neurological disease, ENT and pulmonary involvement
- Proportion of patients decreased, with an improvement in lung function tests
Safety
| Outcome | Values |
|---|---|
| Adverse events | Benralizumab 16% |
| Discontinued benralizumab | Benralizumab 13% |
- Adverse events: of 121 patients
Original publication
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. Lancet Rheumatol. Published 6 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →